The Pulse
Healthleap Raises $38M to Expand AI Hospital Screening
Healthleap announced $38 million in seed and Series A funding for software that scans hospital records and flags inpatients who may need closer review. The startup says its system is used in more than 50 hospitals and does not diagnose pati
AI.info Team · Written with AI ·
Healthleap announced $38 million in seed and Series A funding on October 7, 2026, to expand software that flags hospitalized patients who may have overlooked or undiagnosed conditions. The rounds comprise an $8 million seed co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures, according to TechCrunch. The company has not disclosed its valuation.
From dietitian tool to hospital-wide screening
Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap began with a clinical nutrition product Jemima built for dietitians. The company later broadened its focus to help hospital teams find patients who may be at risk of conditions such as malnutrition or delirium. Josiah Meyer, the company’s co-founder and CEO, told TechCrunch the platform now operates in more than 50 hospitals.
Healthleap connects to a hospital’s electronic health record system and uses language models to extract clues from clinicians’ written notes, including mentions of weight loss or difficulty swallowing. It combines those findings with structured data such as lab results and vital signs, then surfaces patients for further review. “Each morning, we write a risk score into the care team’s existing workflow with a dashboard accessible that holds additional information about the patients’ trends,” Meyer told TechCrunch.
The software does not diagnose patients. It places risk information in the care team’s existing workflow so clinicians can decide whether to investigate further. That distinction matters: the product is designed to prioritize review, not make clinical decisions or replace a diagnosis.
More conditions still need validation
Healthleap currently screens for malnutrition and delirium, according to TechCrunch. Its programs for aspiration pneumonia, pressure ulcers and congestive heart failure readmission risk are undergoing further clinical validation, Meyer said. The company’s announcement also described those conditions as part of its wider push to identify more risks in inpatient records.
Healthleap says its malnutrition program at the Hospital of the University of Pennsylvania produced $23.8 million in annualized financial impact. The company attributed $6.3 million to additional reimbursement and $17.5 million to shorter hospital stays. Those figures are the company’s reported results for one hospital program, not an independently established outcome for every customer.
Healthleap says it has grown from three hospital partners to more than 50 over the past year, with customers including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Meyer told TechCrunch that revenue increased more than tenfold over the same period, without disclosing the underlying figures. The company’s LinkedIn announcement also said its system screens more than half a million patients a year.
Contracts tie fees to hospital size and outcomes
The startup sells three-year contracts priced by a hospital’s licensed bed count and also offers outcome-based pricing, TechCrunch reported. Meyer said Healthleap bases its outcome measures on financial returns validated and attributed by hospital finance teams. He told the publication that each customer had seen at least a fivefold “hard ROI,” with some reporting more than 20 times the contract price in annual total returns.
Healthleap plans to use the new funding for engineering, product development, sales and customer success, while adding support for more conditions. Meyer said the company aims to cover more than 40 major health conditions and eventually expand into outpatient and home care. The next near-term test is whether the additional screening programs can complete clinical validation and deliver results beyond the malnutrition program the company has already deployed.